LivaNova Corp (LIVN): מקדם מחיר להכנסות

LivaNova PLC is currently optimizing its operational processes, focusing on profitable neuromodulation and cardiac surgery systems. The market capitalization-to-revenue ratio reflects the market valuation of this strategy, where the 3.30 mark characterizes this parameter. Growth is supported by alliances with clinics to develop stimulators, as well as joint research with physicians into therapy methods for epilepsy and depression.

Steady demand for LivaNova PLC (LIVN) neuromodulation and cardiac surgery systems allows for the assessment of business scaling efficiency through market value. An analysis of the price-to-sales multiple demonstrates the capitalization ratio relative to annual turnover, helping investors determine the premium paid for revenue and correlate the expansion rates of medical technologies with the current share price to identify the asset's fair value.